Abstract
Luteinizing hormone (LH) and its homologue, human chorionic gonadotropin (hCG), are very important regulators of the reproductive system. These hormones stimulate various types of G proteins—primarily, Gs and Gq proteins—by binding to the specific LH-hCG receptor, which leads to the activation of adenylate cyclase (AC) and phospholipase C, respectively. It has been suggested that many side effects of LH and hCG are associated with low selectivity of their effect on G proteins. Low-molecular agonists of LH-hCG receptor developed on the basis of thienopyrimidine derivatives do not cause these side effects, and differences in the interaction with G proteins may be ones of the cause for this. To test this, a comparative study of the effect of hCG and synthesized by us thienopyrimidine derivative, 5-amino-N-tert-butyl-2-(methylsulfanyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]pyrimidine-6-carboxamide (TP03) on the AC activity and GTP binding of G proteins in plasma membranes isolated from the rat ovaries and testes was performed. Cholera toxin (CT) and pertussis toxin (PT) were used to selectively switch off the signal transduction via Gs and Gi/o proteins, the peptide corresponding to the C-terminal segment 349–359 of the Gαq subunit was used to suppress Gq-dependent cascades. It was shown that treatment of ovarian and testicular membranes with CT resulted in suppression of TP03 and hCG stimulatory effects on the AC activity, but in different ways influenced the GTP binding stimulation: it completely blocked the effect of 10–6 M TP03 and reduced by 45–46% the effect of hCG (10–8 M). Preincubation of membranes with the peptide 349–359 reduced the hCG stimulatory effect on GTP binding by 34 (ovaries) and 45% (testes), but did not affect the corresponding effect of 10–6 M TP03. Preincubation with the peptide 349–359 also reduced the GTP stimulatory effect of 10–4 M TP03, but to a small extent. The obtained data indicate that, in contrast to hCG, the targets of which in the ovaries and testes are Gs and Gq proteins, the action of TP03 is realized mainly via Gs proteins. Only at a concentration that exceeds EC50 by two orders TP03 is capable to relatively weakly activate Gq proteins. The PT treatment of the membranes did not affect the effects of TP03 and hCG, which indicates the lack of their effective interaction with Gi/o proteins. Thus, the selectivity of activation of Gs-dependent cascades responsible for the synthesis and production of steroid hormones is a significant advantage of low-molecular agonists of LH-hCG receptor over gonadotropins.
Similar content being viewed by others
Abbreviations
- AC:
-
adenylate cyclase
- PT:
-
pertussis toxin
- LH:
-
luteinizing hormone
- hCG:
-
human chorionic gonadotropin
- CT:
-
cholera toxin
- GppNHp:
-
β,γ-imidoguanosine-5'-triphosphate
- TP03:
-
5-amino-N-tert-butyl-2-(methylsulfanyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]pyrimidine-6-carboxamide
- VEGF:
-
vascular endothelial growth factor
References
Bakhtyukov, A.A. and Shpakov, A.O., The molecular mechanisms of steroidogenesis regulation in Leydig cells, Tsitologiia, 2016, vol. 58, no. 9, pp. 666–678.
Casarini, L., Reiter, E., and Simoni, M., B-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line, Mol. Cell. Endocrinol., 2016, vol. 437, pp. 11–21.
Chillar, A., Wu, J., Cervantes, V., and Ruan, K.H., Structural and functional analysis of the C-terminus of Gαq in complex with the human thromboxane A2 receptor provides evidence of constitutive activity, Biochemistry, 2010, vol. 49, pp. 6365–6374.
Derkach, K.V., Dar’in, D.V., Lobanov, P.S., and Shpakov, A.O., Intratesticular, intraperitoneal, and oral administration of thienopyrimidine derivatives increases the testosterone level in male rats, Dokl. Biol. Sci., 2014, vol. 459, no. 1, pp. 326–329.
Derkach, K.V., Bondareva, V.M., Chistyakova, O.V., Berstein, L.M., and Shpakov, A.O., The effect of long-term intranasal serotonin treatment on metabolic parameters and hormonal signaling in rats with high-fat diet/low-dose streptozotocin-induced type 2 diabetes, Int. J. Endocrinol., 2015, vol. 2015, pp. 245459.
Derkach, K.V., Dar’in, D.V., Bakhtyukov, A.A., Lobanov, P.S., and Shpakov, A.O., In vitro and in vivo studies of functional activity of new low molecular weight agonists of the luteinizing hormone receptor, Biochemistry (Moscow). Suppl. Ser. A: Membr. Cell Biol., 2016, vol. 10, no. 4, pp. 294–300.
Gerrits, M., Mannaerts, B., Kramer, H., Addo, S., and Hanssen, R., First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age, J. Clin. Endocrinol. Metab., 2013, vol. 98, pp. 1558–1566.
Gilchrist, R.L., Ryu, K.S., Ji, I., and Ji, T.H., The luteinizing hormone/chorionic gonadotropin receptor has distinct transmembrane conductors for cAMP and inositol phosphate signals, J. Biol. Chem., 1996, vol. 271, pp. 19283–19287.
Gudermann, T., Kalkbrenner, F., and Schultz, G., Diversity and selectivity of receptor–G protein interaction, Annu. Rev. Pharmacol. Toxicol., 1996, vol. 36, pp. 429–460.
Heitman, L.H., and Ijzerman, A.P., G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands, Med. Res. Rev., 2008, vol. 28, pp. 975–1011.
Jiang, X., Dias, J.A., and He, X., Structural biology of glycoprotein hormones and their receptors: insights to signaling, Mol. Cell. Endocrinol., 2014, vol. 382, pp. 424–451.
Kleinau, G. and Krause, G., Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms, Endocr. Rev., 2009, vol. 30, pp. 133–151.
Nataraja, S.G., Yu, H.N., and Palmer, S.S., Discovery and development of small molecule allosteric modulators of glycoprotein hormone receptors, Front. Endocrinol. (Lausanne), 2015, vol. 6, p. 142.
Puett, D., Li, Y., DeMars, G., Angelova, K., and Fanelli, F., A functional transmembrane complex: the luteinizing hormone receptor with bound ligand and G protein, Mol. Cell. Endocrinol., 2007, vol. 260, pp. 126–136.
Shpakov, A.O., New achievements in the development and study of the mechanisms of action of the low molecular weight agonists of receptors of the thyroid-stimulating and the luteinizing hormones, Tsitologiya, 2015, vol. 57, no. 3, pp. 167–176.
Shpakov, A.O., Shpakova, E.A., Tarasenko, I.I., Derkach, K.V., and Vlasov, G.P., The peptides mimicking the third intracellular loop of 5-hydroxytryptamine receptors of the types 1B and 6 selectively activate G proteins and receptor-specifically inhibit serotonin signaling via the adenylyl cyclase system, Int. J. Pept. Res. Ther., 2010, vol. 16, pp. 95–105.
Shpakov, A.O., Dar’in, D.V., Derkach, K.V., and Lobanov, P.S., The stimulating influence of thienopyrimidine compounds on the adenylyl cyclase systems in the rat testes, Dokl. Biochem. Biophys., 2014a, vol. 456, no. 1, pp. 104–107.
Shpakov, A.O., Derkach, K.V., Dar’in, D.V., and Lobanov, P.S., Activation of adenylyl cyclase by thienopyrimidine derivatives in rat testes and ovaries, Cell Tissue Biol., 2014b, vol. 8, no. 5, pp. 400–406.
Sivaraj, K.K., Li, R., Albarran-Juarez, J., Wang, S., Tischner, D., Grimm, M., Swiercz, J.M., Offermanns, S., and Wettschureck, N., Endothelial Gαq/11 is required for VEGF-induced vascular permeability and angiogenesis, Cardiovasc. Res., 2015, vol. 108, pp. 171–180.
Szkudlinski, M.W., New frontier in glycoprotein hormones and their receptors structure–function, Front. Endocrinol. (Lausanne), 2015, vol. 6, p. 155.
Troppmann, B., Kleinau, G., Krause, G., and Gromoll, J., Structural and functional plasticity of the luteinizing hormone/ choriogonadotrophin receptor, Hum. Reprod. Update, 2013, vol. 19, pp. 583–602.
van de Lagemaat, R., Raafs, B.C., van Koppen, C., Timmers, C.M., Mulders, S.M., and Hanssen, R.G., Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and Rec-LH, Endocrinology, 2011, vol. 152, pp. 4350–4357.
van de Lagemaat, R., Timmers, C.M., Kelder, J., van Koppen, C., Mosselman, S., and Hanssen, R.G., Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor, Hum. Reprod., 2009, vol. 24, pp. 640–648.
van Koppen, C.J., Zaman, G.J., Timmers, C.M., Kelder, J., Mosselman, S., van de Lagemaat, R., Smit, M.J., and Hanssen, R.G., A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor, Naunyn Schmiedebergs Arch. Pharmacol., 2008, vol. 378, pp. 503–514.
Zeng, H., Zhao, D., Yang, S., Datta, K., and Mukhopadhyay, D., Heterotrimeric Gαq/Gα11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling, J. Biol. Chem., 2003, vol. 278, pp. 20738–20745.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © K.V. Derkach, A.A. Bakhtyukov, A.A. Shpakov, D.V. Dar’in, A.O. Shpakov, 2017, published in Tsitologiya, 2017, Vol. 59, No. 7, pp. 474–481.
Rights and permissions
About this article
Cite this article
Derkach, K.V., Bakhtyukov, A.A., Shpakov, A.A. et al. Specificity of heterotrimeric G protein regulation by human chorionic gonadotropin and low-molecular agonist of luteinizing hormone receptor. Cell Tiss. Biol. 11, 475–482 (2017). https://doi.org/10.1134/S1990519X17060037
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990519X17060037